Stolper Co Sells 4,339 Shares of CVS Health Co. (NYSE:CVS)

Stolper Co reduced its stake in shares of CVS Health Co. (NYSE:CVS – Get Rating) by 16.7% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 21,585 shares of the pharmacy operator’s stock after selling 4,339 shares during the period. Stolper Co’s holdings in CVS Health were worth $2,012,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the stock. BRYN MAWR TRUST Co lifted its holdings in shares of CVS Health by 1.5% during the 2nd quarter. BRYN MAWR TRUST Co now owns 6,459 shares of the pharmacy operator’s stock worth $598,000 after acquiring an additional 98 shares during the last quarter. Cobblestone Capital Advisors LLC NY lifted its holdings in shares of CVS Health by 3.3% during the 3rd quarter. Cobblestone Capital Advisors LLC NY now owns 3,136 shares of the pharmacy operator’s stock worth $299,000 after acquiring an additional 100 shares during the last quarter. IFG Advisors LLC lifted its holdings in shares of CVS Health by 4.0% during the 3rd quarter. IFG Advisors LLC now owns 2,667 shares of the pharmacy operator’s stock worth $254,000 after acquiring an additional 102 shares during the last quarter. First National Trust Co lifted its holdings in shares of CVS Health by 2.9% during the 3rd quarter. First National Trust Co now owns 3,640 shares of the pharmacy operator’s stock worth $347,000 after acquiring an additional 104 shares during the last quarter. Finally, Pinnacle Wealth Planning Services Inc. lifted its holdings in shares of CVS Health by 1.0% during the 3rd quarter. Pinnacle Wealth Planning Services Inc. now owns 10,025 shares of the pharmacy operator’s stock worth $956,000 after acquiring an additional 104 shares during the last quarter. 77.29% of the stock is owned by institutional investors.

CVS Health Trading Down 1.9 %

Shares of NYSE CVS traded down $1.46 during midday trading on Friday, hitting $74.37. 16,807,803 shares of the company traded hands, compared to its average volume of 9,656,588. CVS Health Co. has a 12-month low of $73.91 and a 12-month high of $109.69. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.67 and a current ratio of 0.94. The stock has a 50-day moving average price of $85.40 and a 200 day moving average price of $93.04. The firm has a market cap of $95.50 billion, a P/E ratio of 23.84, a P/E/G ratio of 1.17 and a beta of 0.65.

CVS Health (NYSE:CVS – Get Rating) last announced its quarterly earnings results on Wednesday, February 8th. The pharmacy operator reported $1.99 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.92 by $0.07. CVS Health had a net margin of 1.29% and a return on equity of 15.75%. The company had revenue of $83.85 billion for the quarter, compared to analysts’ expectations of $76.37 billion. During the same quarter in the previous year, the company earned $1.98 earnings per share. CVS Health’s quarterly revenue was up 9.5% on a year-over-year basis. As a group, analysts expect that CVS Health Co. will post 8.84 earnings per share for the current year.

CVS Health Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, May 1st. Investors of record on Friday, April 21st will be paid a dividend of $0.605 per share. This represents a $2.42 annualized dividend and a yield of 3.25%. The ex-dividend date of this dividend is Thursday, April 20th. CVS Health’s payout ratio is currently 77.56%.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on CVS. Raymond James decreased their target price on shares of CVS Health from $115.00 to $110.00 and set an “outperform” rating on the stock in a research report on Thursday, February 9th. StockNews.com began coverage on shares of CVS Health in a research report on Thursday. They issued a “buy” rating on the stock. Morgan Stanley lifted their target price on shares of CVS Health from $119.00 to $120.00 and gave the stock an “overweight” rating in a research report on Friday, January 13th. Royal Bank of Canada reiterated an “outperform” rating and issued a $115.00 target price on shares of CVS Health in a research report on Thursday, February 9th. Finally, Barclays decreased their target price on shares of CVS Health from $118.00 to $110.00 and set an “overweight” rating on the stock in a research report on Thursday, February 9th. Three research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $119.65.

CVS Health Profile

(Get Rating)

CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Pharmacy Services, Retail or Long-Term Care, Health Care Benefits, and Corporate and Other. The Pharmacy Services segment focuses on the pharmacy benefit management solutions.